Please Wait
Applying Filters...
menu
    • menu
    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-08-25

    Virtual Booth

    An Enquiry

    Menu

    Teplizumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    First T1D Treatment Licensed for Stage 3 Delay in Adults and Kids
    First T1D Treatment Licensed for Stage 3 Delay in Adults and Kids

    15 Aug 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-08-15/first-disease-modifying-type-1-diabetes-treatment-licensed-to-delay-the-onset-of-symptomatic-stage-3-autoimmune-type-1-diabetes-t1d-in-adult-and-pae

    PHARMAWEB
    15 Aug 2025
    Share Share
    Sanofi-Aventis`s Tzield Receives Approval in Canada
    Sanofi-Aventis`s Tzield Receives Approval in Canada

    05 May 2025

    // HEALTH CANADA

    http://pdf.hres.ca/dpd_pm/00080446.PDF

    HEALTH CANADA
    05 May 2025
    Share Share
    Sanofi’s Tzield (Teplizumab) Recieves Approval in Canada
    Sanofi’s Tzield (Teplizumab) Recieves Approval in Canada

    05 May 2025

    // HEALTH CANADA

    https://pdf.hres.ca/dpd_pm/00080446.PDF

    HEALTH CANADA
    05 May 2025
    Share Share
    Sanofi to acquire Provention Bio for $2.9 billion
    Sanofi to acquire Provention Bio for $2.9 billion

    14 Mar 2023

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-13-06-00-00-2625367

    PRESS RELEASE
    14 Mar 2023
    Share Share
    Provention Bio Announces Closing of Second Tranche with Hercules Capital
    Provention Bio Announces Closing of Second Tranche with Hercules Capital

    02 Feb 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/provention-bio-announces-closing-of-second-tranche-with-hercules-capital-to-support-us-commercial-launch-of-tzield-301737909.html

    PR NEWSWIRE
    02 Feb 2023
    Share Share
    2022 drug approvals: Biopharma delivered 37 new drugs
    2022 drug approvals: Biopharma delivered 37 new drugs

    03 Jan 2023

    // Kevin Dunleavy FIERCE PHARMA

    https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come

    Kevin Dunleavy FIERCE PHARMA
    03 Jan 2023
    Share Share